Introduction
Comprehending the problems faced by patients with a given disease is an essential aspect of medical care, although always a challenge. Health professionals, in general, and physicians, in particular, tend to focus on a limited number of parameters that can be readily measured. While this approach is appropriate for determining organ involvement and disease activity as well as making therapeutic decisions, it can fall short when evaluating over-all patient well-being or disease-related cost. Exploring the perspective of patients is particularly important in a heterogeneous disease such as systemic lupus erythematosus (SLE), because individual patient problems may vary greatly in severity and duration. Thus, ideally, an outcome measurement should provide a comprehensive picture of the different problems experienced by the individual patient, and should not only focus on biomedical outcome measures.
Achieving such a comprehensive view of SLE patients' problems will be a difficult task. Why then should rheumatologists take on such challenge? Since, despite considerable work, such endeavour might produce a useful outcome, what is there to gain? There are Lupus several answers to these important questions, which, we think, will stand in the end. One of the answers comes from occupational therapy, where function and disability are the main focus of attention. While physicians uncommonly focus on disability in their professional approach, but rather on stopping disease from causing disability, occupational therapists are trained to mainly see this other side of the patient. By doing so, however, occupational therapists and other health professionals will need our effort to set the stage for optimal patient care. It is the physicians and nurses, on the one hand, and the patients, on the other, who know intimately about the manifestations of SLE, and can therefore link the available information into a meaningful framework.
In addition to providing the information for a solid background for all health professionals, a comprehensive definition of the problems faced by SLE patients will be a powerful tool for dealing with both politics and decisions by health authorities. While very important on an emotional level, the example of single cases can never substitute for such data. If we do not understand the variety of problems our patients face, there is little we can do about them on either a medical level or on a political one. Moreover, applying comprehensive models of functioning and health will be the base for a true assessment of the burden of disease. These comprehensive models will then allow comparisons between different diseases, and lead political decision makers to informed decisions with regard to the allocation of resources, laws, and care provision.
Finally, such a comprehensive understanding will hopefully lead to better tools for daily practice. Fatigue scales for example, have found their way into lupus trials and care, 1 although derived from outside our own field. It is important that neither fatigue nor quality of life measures were found associated with SLE disease activity in cross-sectional studies, 2 suggesting that important aspects of the lupus patient's disease burdenpotentially including treatable conditions -are not responding to treatment despite intensive medical care for internal organ disease. Along similar lines, we may want to develop a lupus skin score showing the patient's view on disease-related problems. Such a score could become be a valuable tool for guiding therapeutic efforts to control skin manifestations of SLE or cutaneous lupus. After all, it is the impaired function of a patient in daily life, and the ensuing loss in life quality, that will influence patient decisions about accepting the risks or side effects for specific treatments.
These concepts pertain for practically any given disease, and the World Health Assembly has therefore responded by approving the new International Classification of Functioning (ICF), 3 the first universally accepted way to classify and describe functioning, disability and health in persons with a condition. Following the WHO definition of health, the ICF framework is based on the bio-psycho-social model. The ICF models daily functioning of patients with different health conditions within the framework of a classification. Thus, the ICF offers a frame of reference to describe the functioning of patients with a certain health condition.
Technically, the ICF classification has two parts, each consisting of separate components. Part 1 covers functioning and disability and includes the components body functions (b) and structures (s) as well as daily activities and participation (d). Part 2 covers the context, comprising environmental (e) and personal factors. Each component is divided into several chapters, which represent health domains. Examples are the chapter neuromusculoskeletal and movement-related functions within the component body functions and the chapter self-care within the component activity and participation. Each chapter then consists of categories, which are the factual units of the classification. 3 In total, the ICF classification includes more than 1400 categories, thus limiting use in clinical practice. It is possible, however, to derive practical tools from the classification, which are called ICF Core Sets. 4, 5 ICF Core Sets are short lists of selected ICF categories, which are useful for modelling the function of patients with a specific disease. To date, ICF Core Sets have been developed for 12 chronic conditions. 6, 7 The one example in rheumatology is the ICF Core Set for rheumatoid arthritis. 8 Core Sets for several other chronic conditions are currently being developed.
It is important to reiterate that the ICF is a framework, and the ICF Core Sets are practical tools to classify and describe patient functioning, using a classification of world-wide acceptance. However, at this point, the categories included in ICF core sets do not define the basis of measurement. Instead, the ICF Core Sets can serve as reference framework when selecting instruments for measuring symptoms and consequences of the disease, or when defining the elements covered by specific measures. The ICF and the ICF Core Sets may become the base for further developing such measures. In this way, the ICF is an important concept and ICF Core Sets are interesting tools for the further development of clinical (and rehabilitation) science.
The development of ICF Core Sets for SLE poses considerable complexities and even obstacles. SLE is prototypically a heterogenous disease, perhaps even more so than other multisystem disorders. Not only is there a wide range of both disease activity and severity, but therapy varies markedly in intensity as well as toxicity, all of which can influence patient outcomes. SLE involves essentially all organ systems, including the CNS, and may induce various functional problems as well as damage in the brain. The various possible CNS manifestations of the disease, and their treatment, will further add to the heterogeneity of problems faced by SLE patients. On the other hand, there are typical symptoms which will afflict most SLE patients, regardless of their main organ manifestations. Therefore, ICF Core Sets for SLE will need to address the full spectrum of problems encountered both with SLE in general, and with the most common forms of SLE organ involvement in particular. We expect that there will be overlapping core sets with other diseases afflicting the same organ system, such as between SLE with lupus arthritis and rheumatoid arthritis, or between SLE renal disease and other forms of glomerulonephritis.
The most commonly used measures in SLE are activity scores, such as (in alphabetical order) the British Isles Lupus Assessment Group index (BILAG), 9 the European Consensus Lupus Activity Measurement (ECLAM), 10 the SLE Index Score (SIS), 11 the Systemic Lupus Activity Measure (SLAM), 12 or the SLE Disease Activity Index (SLEDAI). 13 All of these scores contain information on a variety of symptoms experienced by the patient (Table 1 ), in addition to a variety of laboratory and other parameters.
Regarding these symptoms, there are important differences among the organ systems affected. For example, general, mucocutaneous, or neurological symptoms receive prominent attention, whereas other important organ manifestations are scarcely considered (Table 1 ). In part, this relative imbalance is due to a lack of symptoms, such as often is the case in early renal disease, although the activity measures account for such manifestation by using laboratory evaluations instead. Also, the symptoms graded here serve the purpose of indicating activity; they do not weigh damage or well-being, and some are quite uncommon features.
In addition to the activity scales, which correlate well with each other, 14 there is one wellestablished SLE damage index, the Systemic Lupus International Collaborative Clinics/American College of Rheumatology (SLICC/ACR) damage index. 15 Moreover, several non-specific quality of lifemeasures have been successfully used in patients with SLE. 1,2 While useful in pointing to candidate ICF categories, these indices, however, will neither allow for functional measurement nor will they directly indicate the most relevant categories in understanding the functional disease burden of SLE.
To meet the need for new outcomes measures for SLE, we here propose a process to lead to comprehensive ICF core sets for patients with SLE. While this plan was first derived in a meeting conducted in Munich in November 2004, and bolstered after interactions with several other centres, we would like to invite worldwide participation in this effort. Only by cooperation and exchange can we can reach the goal of developing ICF core sets for SLE (and possibly including isolated cutaneous lupus) to depict comprehensively the functional problems faced by patients all over the world, including their many diverse and confusing variations.
Methodological approach to develop ICF Core Sets for SLE

Types of ICF Core Sets that will be developed
The development of ICF Core Sets for SLE will include two versions: The Brief ICF Core Set for SLE to be used in clinical trials. Thus, the Brief ICF Core Set for SLE will include a list of ICF categories with as few categories as possible to be practical, but as many as necessary to describe as comprehensively as possible the spectrum of problems in functioning of patients with SLE for clinical studies.
The Comprehensive ICF Core Set will be applicable for guiding multidisciplinary assessment in patients with SLE. Thus, more ICF categories will need to be included to adequately describe, in a multidisciplinary assessment, the typical spectrum of problems in functioning of any patient with SLE. Two additional add-on ICF Core Sets Lists will be developed. The first will be for mucocutaneous manifestations, while the second will be for musculoskeletal involvement, the latter based on the existing core set for rheumatoid artritis (RA).
Based on knowledge gained in the previous ICF Core Set developments, the following methodological approach for the Core Set development is projected.
Study design
As is the standard procedure for the ICF Core Sets, the SLE core sets will be defined at a consensus conference, which will integrate i) a systematic review of the literature regarding the outcome measures used in clinical trials and selected observational studies, ii) focus groups or semi-structured interviews with SLE patients, iii) a Delphi exercise with world wide involvement of experts, and iv) empirical studies.
With this study design, all relevant perspectives should be adequately addressed. The patient perspective, which is crucial to the success of the project, is addressed both in a qualitative way in focus groups and in a quantitative way in the empirical studies. In addition, we will try to initiate a Delphi exercise for patients. The investigator perspective is addressed in the systematic literature reviews. Finally, various 
Consensus conference
The consensus conference is scheduled for Vienna in mid-2007. Experts in the field of SLE will work together actively to select the ICF categories for the Comprehensive and the Brief Core Set. Based on previous experience, it is proposed to form three groups with seven experts each, including different health professionals, who can work together in the spirit of the multi-professional and multi-disciplinary approach typical for care and research in SLE. The method selected to regulate the group dynamic and the teamwork during the conference is the 'Nominal-Group Technique'. 16 Evidence from empirical studies A systematic review of the concepts of outcome measures used in published studies 17 is being performed. The objectives of the systematic review are to identify outcome measures cited in published studies focusing on individuals with SLE, and to quantify the concepts contained in these measures. The concepts of the retrieved outcome measures will be linked to ICF categories using standardized linking rules. 18 The results from this systematic review of empirical studies should be available in June 2006.
Focus groups with patients
'Focus groups', ie, open interviews with patients in small groups of up to seven people, have been chosen as the most appropriate available qualitative approach for identifying the patient perspective of functioning and health. 19, 20 As compared to individual interviews, focus groups are enriched by interactions in the group, and therefore usually generate additional information. Focus group studies will at least be performed in Europe (Austria) as well as in the US and East Asia. These groups should be completed by the end of August 2006, so that their results can be included in the Delphi exercise and empirical studies (below).
Delphi exercise
A Delphi exercise will encourage experts to identify problems they appreciate for their patients in a feedback procedure based on information-technology, 21 with the goal of shaping common consensus. Balanced involvement with regard to WHO regions and professions will be facilitated by directly approaching experts from both underrepresented areas (eg, Africa, South America) and fields (eg, psychologists, physiotherapists). Delphi exercises will start in September 2006, and should be finished by January 2007. We will try to also initiate an SLE patient Delphi exercise with a similar approach. 
Conclusions
In embarking on the project to define ICF Core Sets for SLE, we here have described the background and the approach for development of both a Comprehensive and a Brief ICF Core Set for SLE. It is interesting, in this regard, that SLE activity scores include important information on some features of the disease, which link to the components body functions and body structures of the ICF classification (Table 1) . However, it is likewise obvious that there is no one-to-one linkage, demonstrating systematic differences in the approach, and that some symptoms could not be linked to an ICF category. Moreover, when considering the patient perspective, we may also need to assess the other components, namely the individuals' functioning in daily life and social participation. Since functioning and participation in daily living contribute significantly to the quality of life, they are highly relevant aspects for the comprehensive assessment of a patient with SLE.
Comprehensive assessment and understanding of individual daily problems requires a strong focus on patient perspectives, which most likely differ between cultures. The ICF includes the environment as a contextual factor, which also differs between countries and cultures. Therefore, this project will accommodate this international perspective both in the selection of locations for patient focus groups and the participation of additional experts for the Delphi exercise.
The development of the SLE ICF Core Sets will be an inclusive and open process. We therefore encourage both SLE clinical experts and SLE patient representatives to actively participate in the process. Individuals, institutions and associations, can be formally associated as partners of the project. Everybody interested should please contact the project coordinators (MA, TS, DP). We believe that it is time develop the tools to assess the life of patients with SLE with greater clarity precision and thereby promote treatments to enhance their quality of life.
